

# Nataschia Campostrini

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11199592/publications.pdf>

Version: 2024-02-01

48  
papers

2,502  
citations

186265

28  
h-index

243625

44  
g-index

48  
all docs

48  
docs citations

48  
times ranked

3456  
citing authors

#	ARTICLE	IF	CITATIONS
1	A single dialysis session of hemodiafiltration with sorbent-regenerated endogenous ultrafiltrate reinfusion (HFR) removes hepcidin more efficiently than bicarbonate hemodialysis: a new approach to containing hepcidin burden in dialysis patients?. <i>Journal of Nephrology</i> , 2018, 31, 297-306.	2.0	8
2	Disturbed iron metabolism in erythropoietic protoporphyria and association of GDF15 and gender with disease severity. <i>Journal of Inherited Metabolic Disease</i> , 2017, 40, 433-441.	3.6	20
3	Identification of novel mutations in hemochromatosis genes by targeted next generation sequencing in Italian patients with unexplained iron overload. <i>American Journal of Hematology</i> , 2016, 91, 420-425.	4.1	22
4	Toward Worldwide Hepcidin Assay Harmonization: Identification of a Commutable Secondary Reference Material. <i>Clinical Chemistry</i> , 2016, 62, 993-1001.	3.2	73
5	Serum Hepcidin and Iron Absorption in Paediatric Inflammatory Bowel Disease. <i>Journal of Crohn's and Colitis</i> , 2016, 10, 566-574.	1.3	43
6	Detection of a rare mutation in the ferroportin gene through targeted next generation sequencing. <i>Blood Transfusion</i> , 2016, 14, 531-534.	0.4	7
7	Does TMPRSS6 RS855791 Polymorphism Contribute to Iron Deficiency in Treated Celiac Disease?. <i>American Journal of Gastroenterology</i> , 2015, 110, 200-202.	0.4	23
8	Iron deficiency in the elderly population, revisited in the hepcidin era. <i>Frontiers in Pharmacology</i> , 2014, 5, 83.	3.5	97
9	Glycol-split nonanticoagulant heparins are inhibitors of hepcidin expression in vitro and in vivo. <i>Blood</i> , 2014, 123, 1564-1573.	1.4	62
10	Hepcidin levels in chronic hemodialysis patients: a critical evaluation. <i>Clinical Chemistry and Laboratory Medicine</i> , 2014, 52, 613-9.	2.3	27
11	Oversulfated heparins with low anticoagulant activity are strong and fast inhibitors of hepcidin expression in vitro and in vivo. <i>Biochemical Pharmacology</i> , 2014, 92, 467-475.	4.4	38
12	The A736V TMPRSS6 polymorphism influences hepcidin and iron metabolism in chronic hemodialysis patients: TMPRSS6 and hepcidin in hemodialysis. <i>BMC Nephrology</i> , 2013, 14, 48.	1.8	20
13	Serum hepcidin levels and muscle iron proteins in humans injected with low or high dose erythropoietin. <i>European Journal of Haematology</i> , 2013, 91, 74-84.	2.2	23
14	Serum Hepcidin in Inflammatory Bowel Diseases. <i>Inflammatory Bowel Diseases</i> , 2013, 19, 2166-2172.	1.9	46
15	Iron Status Independently Associates With Bone Mineral Density At Population Level. Insights From The Val Borbera Study. <i>Blood</i> , 2013, 122, 4672-4672.	1.4	0
16	Serum levels of the hepcidin-20 isoform in a large general population: The Val Borbera study. <i>Journal of Proteomics</i> , 2012, 76, 28-35.	2.4	29
17	Increased Serum Hepcidin Levels in Subjects with the Metabolic Syndrome: A Population Study. <i>PLoS ONE</i> , 2012, 7, e48250.	2.5	68
18	Evidence for tissue iron overload in long-term hemodialysis patients and the impact of withdrawing parenteral iron. <i>European Journal of Haematology</i> , 2012, 89, 87-93.	2.2	91

#	ARTICLE	IF	CITATIONS
19	Hepcidin Inhibition by Modified Heparins without Anticoagulant Activity. Blood, 2012, 120, 483-483.	1.4	0
20	Hepcidin Levels and Their Determinants in Different Types of Myelodysplastic Syndromes. PLoS ONE, 2011, 6, e23109.	2.5	95
21	TMPRSS6 rs855791 modulates hepcidin transcription in vitro and serum hepcidin levels in normal individuals. Blood, 2011, 118, 4459-4462.	1.4	97
22	Association of HFE and TMPRSS6 genetic variants with iron and erythrocyte parameters is only in part dependent on serum hepcidin concentrations. Journal of Medical Genetics, 2011, 48, 629-634.	3.2	84
23	A time course of hepcidin response to iron challenge in patients with HFE and TFR2 hemochromatosis. Haematologica, 2011, 96, 500-506.	3.5	70
24	Heparin: a potent inhibitor of hepcidin expression in vitro and in vivo. Blood, 2011, 117, 997-1004.	1.4	127
25	Serum Hepcidin Levels Correlate with Phenotypes of the Metabolic Syndrome At Population Level. Blood, 2011, 118, 348-348.	1.4	10
26	Hepcidin assay in serum by SELDI-TOF-MS and other approaches. Journal of Proteomics, 2010, 73, 527-536.	2.4	47
27	Evaluation of Hepcidin Isoforms in Hemodialysis Patients by a Proteomic Approach Based on SELDI-TOF MS. Journal of Biomedicine and Biotechnology, 2010, 2010, 1-7.	3.0	33
28	Hepcidin is not useful as a biomarker for iron needs in haemodialysis patients on maintenance erythropoiesis-stimulating agents. Nephrology Dialysis Transplantation, 2010, 25, 3996-4002.	0.7	82
29	Hepcidin Levels and Their Determinants In Different Types of Myelodysplastic Syndromes. Blood, 2010, 116, 4250-4250.	1.4	0
30	HFE Mutations Modulate the Effect of Iron on Serum Hepcidin-25 in Chronic Hemodialysis Patients. Clinical Journal of the American Society of Nephrology: CJASN, 2009, 4, 1331-1337.	4.5	27
31	Reduced serum hepcidin levels in patients with chronic hepatitis C. Journal of Hepatology, 2009, 51, 845-852.	3.7	148
32	High resolution preparation of monocyte-derived macrophages (MDM) protein fractions for clinical proteomics. Proteome Science, 2009, 7, 4.	1.7	8
33	Results of the first international round robin for the quantification of urinary and plasma hepcidin assays: need for standardization. Haematologica, 2009, 94, 1748-1752.	3.5	161
34	Alterations of systemic and muscle iron metabolism in human subjects treated with low-dose recombinant erythropoietin. Blood, 2009, 113, 6707-6715.	1.4	70
35	Iron Metabolism and Erythropoietic Stress in Myelodysplastic Syndromes.. Blood, 2009, 114, 1752-1752.	1.4	1
36	Application of partial least squares discriminant analysis and variable selection procedures: a 2D-PAGE proteomic study. Analytical and Bioanalytical Chemistry, 2008, 390, 1327-1342.	3.7	48

#	ARTICLE	IF	CITATIONS
37	Acquired iron overload associated with antitransferrin monoclonal immunoglobulin: A case report. American Journal of Hematology, 2008, 83, 932-934.	4.1	6
38	Clinical, pathological, and molecular correlates in ferroportin disease: A study of two novel mutations. Journal of Hepatology, 2008, 49, 664-671.	3.7	39
39	Measurement of urinary hepcidin levels by SELDI-TOF-MS in HFE-hemochromatosis. Blood Cells, Molecules, and Diseases, 2008, 40, 347-352.	1.4	54
40	Advances in Quantitative Hepcidin Measurements by Time-of-Flight Mass Spectrometry. PLoS ONE, 2008, 3, e2706.	2.5	176
41	Results of the First International Round Robin for the Quantification of Urinary and Plasma Hepcidin: Need for Standardization. Blood, 2008, 112, 120-120.	1.4	7
42	Measurement of Urinary Hepcidin Levels by SELDI-TOF-MS in HFE-Hemochromatosis.. Blood, 2007, 110, 2668-2668.	1.4	0
43	Numerical approaches for quantitative analysis of two-dimensional maps: A review of commercial software and home-made systems. Proteomics, 2005, 5, 654-666.	2.2	98
44	Spot overlapping in two-dimensional maps: A serious problem ignored for much too long. Proteomics, 2005, 5, 2385-2395.	2.2	130
45	Proteome analysis in the clinical chemistry laboratory: Myth or reality?. Clinica Chimica Acta, 2005, 357, 123-139.	1.1	99
46	Proteomic analysis of an orthotopic neuroblastoma xenograft animal model*1. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2004, 808, 279-286.	2.3	14
47	Study of proteomic changes associated with healthy and tumoral murine samples in neuroblastoma by principal component analysis and classification methods. Clinica Chimica Acta, 2004, 345, 55-67.	1.1	39
48	Comparative two-dimensional mapping of prion protein isoforms in human cerebrospinal fluid and central nervous system. Electrophoresis, 2002, 23, 339-346.	2.4	35